{"id":"galantamine-reminyl","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Vomiting"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Anorexia"},{"rate":"2-5","effect":"Syncope"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking the enzyme acetylcholinesterase, galantamine prevents the breakdown of acetylcholine, leading to increased acetylcholine concentration in synapses. Additionally, galantamine acts as an allosteric potentiating ligand at nicotinic acetylcholine receptors, enhancing their sensitivity to acetylcholine. This dual mechanism aims to improve cognitive function in patients with Alzheimer's disease by compensating for cholinergic neuronal loss.","oneSentence":"Galantamine inhibits acetylcholinesterase to increase acetylcholine levels in the brain, and also acts as an allosteric modulator of nicotinic receptors to enhance cholinergic neurotransmission.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:31:11.636Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mild to moderate Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT01508494","phase":"PHASE2","title":"Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2011-06-29","conditions":"Stroke, Cognitive Impairment","enrollment":47},{"nctId":"NCT04769206","phase":"PHASE1, PHASE2","title":"Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-12-20","conditions":"Endothelial Dysfunction","enrollment":46},{"nctId":"NCT07284290","phase":"PHASE4","title":"Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2025-12-08","conditions":"Dementia With Lewy Bodies, Parkinson Disease Dementia, Healthy Controls","enrollment":120},{"nctId":"NCT07208344","phase":"EARLY_PHASE1","title":"Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2025-07-31","conditions":"Alzheimer Disease (AD)","enrollment":30},{"nctId":"NCT05564169","phase":"PHASE3","title":"Masitinib in Patients With Mild Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"AB Science","startDate":"2026-06","conditions":"Alzheimer Disease","enrollment":600},{"nctId":"NCT07003386","phase":"PHASE2, PHASE3","title":"Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke","status":"RECRUITING","sponsor":"Shanghai Yueyang Integrated Medicine Hospital","startDate":"2025-09-15","conditions":"Acute Ischemic Stroke AIS","enrollment":66},{"nctId":"NCT03124355","phase":"PHASE1","title":"Vagal Stimulation in POTS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2017-09-30","conditions":"Postural Tachycardia Syndrome","enrollment":11},{"nctId":"NCT03384784","phase":"PHASE2","title":"Effect of Galantamine on Inflammation and Cognition","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2017-10-30","conditions":"HIV Associated Cognitive Motor Complex","enrollment":63},{"nctId":"NCT01190748","phase":"PHASE1","title":"Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2004-11","conditions":"Healthy","enrollment":24},{"nctId":"NCT03454646","phase":"PHASE4","title":"Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2024-06-01","conditions":"Alzheimer Disease, Cholinesterase Inhibitors","enrollment":1205},{"nctId":"NCT01872598","phase":"PHASE3","title":"Masitinib in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"AB Science","startDate":"2012-01","conditions":"Alzheimer Disease","enrollment":721},{"nctId":"NCT03547622","phase":"EARLY_PHASE1","title":"Galantamine and CBT4CBT Pilot to Prevent Relapse.","status":"COMPLETED","sponsor":"Yale University","startDate":"2018-05-01","conditions":"Methadone or Buprenorphine Detoxoxification","enrollment":6},{"nctId":"NCT01100775","phase":"PHASE2","title":"Effects of Galantamine on Cognition","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2010-05","conditions":"Schizophrenia","enrollment":12},{"nctId":"NCT05321680","phase":"NA","title":"Withdrawal of Antidementia Drugs in Advanced Dementia (WADAD)","status":"COMPLETED","sponsor":"Centro Hospitalar De São João, E.P.E.","startDate":"2021-03-01","conditions":"Dementia","enrollment":16},{"nctId":"NCT00161044","phase":"NA","title":"An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2004-09","conditions":"Chronic Schizophrenia","enrollment":20},{"nctId":"NCT01012167","phase":"PHASE2","title":"Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2010-02","conditions":"Schizophrenia","enrollment":86},{"nctId":"NCT05102045","phase":"NA","title":"The Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Istanbul Medipol University Hospital","startDate":"2016-09-01","conditions":"Alzheimer Disease","enrollment":27},{"nctId":"NCT02872857","phase":"PHASE1, PHASE2","title":"Subarachnoid Hemorrhage Recovery And Galantamine","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2016-09","conditions":"Subarachnoid Hemorrhage","enrollment":60},{"nctId":"NCT03565809","phase":"","title":"Quality of the Management of Diabetes in Elderly People With Dementia in France","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2017-05-02","conditions":"Alzheimer Disease","enrollment":87816},{"nctId":"NCT00606801","phase":"NA","title":"Galantamine Effects on Cognitive Function in Abstinent Cocaine Users","status":"COMPLETED","sponsor":"Yale University","startDate":"2007-06","conditions":"Cocaine Abuse","enrollment":34},{"nctId":"NCT00176423","phase":"PHASE4","title":"Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2002-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":117},{"nctId":"NCT01951118","phase":"PHASE4","title":"Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2013-10","conditions":"Alzheimer Disease, Mild Cognitive Impairment, Delirium, Dementia, Amnestic, Cognitive Disorders","enrollment":121},{"nctId":"NCT01880099","phase":"NA","title":"A Study to Help People Quit Smoking.","status":"COMPLETED","sponsor":"Yale University","startDate":"2013-12","conditions":"Nicotine Dependence","enrollment":60},{"nctId":"NCT02420327","phase":"NA","title":"Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2014-09","conditions":"Basic Science Study of the Mechanisms of Attentional Enhancement by Compounds Acting on the Nicotinic Receptor","enrollment":43},{"nctId":"NCT02703636","phase":"PHASE4","title":"NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-05-09","conditions":"Mild to Moderate Alzheimer's Disease","enrollment":118},{"nctId":"NCT02365285","phase":"PHASE1, PHASE2","title":"Racial Differences in Vagal Control of Glucose Homeostasis","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2015-03","conditions":"Obesity","enrollment":23},{"nctId":"NCT01669538","phase":"PHASE2","title":"Effect of Galantamine on Short-term Abstinence","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2012-08","conditions":"Tobacco Use Disorder","enrollment":98},{"nctId":"NCT00809835","phase":"PHASE2","title":"Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse","status":"COMPLETED","sponsor":"Yale University","startDate":"2007-12","conditions":"Cocaine Dependence","enrollment":120},{"nctId":"NCT01531153","phase":"NA","title":"Cognitive Enhancement as a Target for Cocaine Pharmacotherapy","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-09","conditions":"Addiction","enrollment":93},{"nctId":"NCT01852110","phase":"PHASE2","title":"Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-22","conditions":"Alzheimer's Disease","enrollment":240},{"nctId":"NCT03014323","phase":"PHASE1","title":"Racial Differences in Vagal Control of Glucose Homeostasis, Chronic Study","status":"WITHDRAWN","sponsor":"Vanderbilt University Medical Center","startDate":"2017-01","conditions":"Insulin Sensitivity, Oxidative Stress","enrollment":""},{"nctId":"NCT00509067","phase":"PHASE2","title":"Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2007-11","conditions":"Schizophrenia","enrollment":43},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT01548638","phase":"PHASE2","title":"Effect of Galantamine on Smoking Abstinence","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2012-02","conditions":"Nicotine Addiction","enrollment":13},{"nctId":"NCT00227994","phase":"PHASE4","title":"Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2003-04","conditions":"Cerebrovascular Accident","enrollment":40},{"nctId":"NCT02234752","phase":"PHASE2","title":"Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia","status":"TERMINATED","sponsor":"Sheppard Pratt Health System","startDate":"2014-09","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":3},{"nctId":"NCT01677754","phase":"PHASE2","title":"A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-10-24","conditions":"Alzheimer's Disease","enrollment":542},{"nctId":"NCT01194336","phase":"","title":"Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2012-02","conditions":"Biomarkers, Pharmacological","enrollment":84},{"nctId":"NCT00741598","phase":"PHASE4","title":"Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2008-09","conditions":"Bipolar Disorder","enrollment":72},{"nctId":"NCT02035982","phase":"PHASE3","title":"Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2010-07","conditions":"Alzheimer's Disease, Dementia","enrollment":40},{"nctId":"NCT00195845","phase":"PHASE4","title":"A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder","status":"COMPLETED","sponsor":"Cambridge Health Alliance","startDate":"2003-04","conditions":"Bipolar Disorder","enrollment":30},{"nctId":"NCT01362686","phase":"NA","title":"Comparative Research of Alzheimer's Disease Drugs","status":"TERMINATED","sponsor":"Indiana University","startDate":"2011-04","conditions":"Dementia, Alzheimer's Disease","enrollment":200},{"nctId":"NCT02283242","phase":"PHASE4","title":"Galantamine Effects in Patients With Metabolic Syndrome","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2014-03","conditions":"Abdominal Obesity Metabolic Syndrome","enrollment":60},{"nctId":"NCT01529619","phase":"PHASE4","title":"Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Alzheimer's Disease","enrollment":52},{"nctId":"NCT02098824","phase":"PHASE2, PHASE3","title":"Symptomatic Treatment of Vascular Cognitive Impairment","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2014-02","conditions":"Mild Cognitive Impairment (Vascular), Mild Cognitive Disorder (Vascular), Vascular Dementia","enrollment":30},{"nctId":"NCT01944436","phase":"","title":"A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2006-09","conditions":"Lewy Body Disease","enrollment":57},{"nctId":"NCT01023425","phase":"NA","title":"Clinical Trial of Donepezil Between the Naive Group and the Switching Group","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2008-02","conditions":"Alzheimer's Disease, Dementia","enrollment":72},{"nctId":"NCT01029132","phase":"NA","title":"Characteristics of Treatment Responders to Galantamine","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2007-04","conditions":"Dementia","enrollment":66},{"nctId":"NCT01417429","phase":"PHASE1","title":"Galantamine Effects on Nicotine Responses in Smokers","status":"COMPLETED","sponsor":"Yale University","startDate":"2010-03","conditions":"Smoking, Tobacco Withdrawal","enrollment":12},{"nctId":"NCT02187276","phase":"","title":"The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia","status":"COMPLETED","sponsor":"Federal University of Minas Gerais","startDate":"2009-06","conditions":"Alzheimer Disease, Late Onset","enrollment":129},{"nctId":"NCT00750529","phase":"PHASE1","title":"Alzheimer and Sleep","status":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2008-11","conditions":"Alzheimer's Disease","enrollment":15},{"nctId":"NCT01009476","phase":"","title":"Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2006-03","conditions":"Dementia, Alzheimer Disease, Dementia, Vascular","enrollment":1134},{"nctId":"NCT00299676","phase":"","title":"An Observational Study of the Safety and Effectiveness of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period","status":"COMPLETED","sponsor":"Janssen-Cilag Pty Ltd","startDate":"2005-05","conditions":"Alzheimer Disease, Dementia, Galantamine","enrollment":61},{"nctId":"NCT01181921","phase":"PHASE4","title":"The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease","status":"TERMINATED","sponsor":"Janssen-Cilag, S.A.","startDate":"2011-05","conditions":"Alzheimer Disease","enrollment":1},{"nctId":"NCT00814801","phase":"PHASE3","title":"An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2007-02","conditions":"Alzheimer's Disease","enrollment":580},{"nctId":"NCT01478633","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2011-09","conditions":"Alzheimer's Disease","enrollment":102},{"nctId":"NCT00551161","phase":"PHASE4","title":"Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2007-08","conditions":"Alzheimer Disease","enrollment":12},{"nctId":"NCT00679627","phase":"PHASE3","title":"A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2008-06","conditions":"Alzheimer's Disease","enrollment":2051},{"nctId":"NCT00814658","phase":"PHASE4","title":"The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life","status":"COMPLETED","sponsor":"Janssen-Cilag Farmaceutica Ltda.","startDate":"2008-06","conditions":"Dementia","enrollment":22},{"nctId":"NCT01921972","phase":"PHASE4","title":"The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2004-11","conditions":"Alzheimer's Disease","enrollment":232},{"nctId":"NCT01734395","phase":"","title":"A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2007-03","conditions":"Alzheimer's Disease","enrollment":1882},{"nctId":"NCT01416948","phase":"PHASE2","title":"Cognitive REmediation After Trauma Exposure Trial = CREATE Trial","status":"TERMINATED","sponsor":"INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium","startDate":"2011-08","conditions":"Posttraumatic Stress Disorder, Traumatic Brain Injury","enrollment":32},{"nctId":"NCT00291421","phase":"","title":"A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's Disease","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2002-07","conditions":"Alzheimer Disease, Dementia, Nervous System Diseases","enrollment":2360},{"nctId":"NCT00369603","phase":"PHASE4","title":"Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients","status":"TERMINATED","sponsor":"Duke University","startDate":"2006-10","conditions":"Alzheimer's Disease","enrollment":4},{"nctId":"NCT00283725","phase":"","title":"Use of Different Treatment Care Methods in Patients With Dementia Associated With Alzheimer's Disease","status":"COMPLETED","sponsor":"Ortho-McNeil Neurologics, Inc.","startDate":"2003-06","conditions":"Dementia, Alzheimer's Disease","enrollment":573},{"nctId":"NCT01054976","phase":"PHASE4","title":"The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2006-10","conditions":"Alzheimer's Disease","enrollment":99},{"nctId":"NCT00566735","phase":"PHASE3","title":"The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2004-07","conditions":"Major Depression, Bipolar Depression, Schizoaffective Disorder","enrollment":39},{"nctId":"NCT01696591","phase":"","title":"The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD","status":"UNKNOWN","sponsor":"Duk Lyul Na","startDate":"2012-03","conditions":"Alzheimer Disease, Dementia, Brain Diseases","enrollment":14},{"nctId":"NCT00969696","phase":"PHASE1","title":"Galantamine Effects on Cognitive Function in Marijuana Users","status":"COMPLETED","sponsor":"Yale University","startDate":"2009-08","conditions":"Memory","enrollment":29},{"nctId":"NCT00297414","phase":"","title":"An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-06","conditions":"Mild Cognitive Impairment","enrollment":1083},{"nctId":"NCT00297362","phase":"","title":"A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Janssen Cilag Pharmaceutica S.A.C.I., Greece","startDate":"2004-06","conditions":"Alzheimer Disease","enrollment":344},{"nctId":"NCT00234637","phase":"PHASE4","title":"Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-11","conditions":"Alzheimer's Disease","enrollment":204},{"nctId":"NCT01372280","phase":"PHASE1","title":"Galantamine Bioequivalence Study of Dr. Reddy's Under Fasting Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2004-10","conditions":"Fasting","enrollment":28},{"nctId":"NCT01372306","phase":"PHASE1","title":"Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2004-10","conditions":"Fed","enrollment":24},{"nctId":"NCT00216593","phase":"PHASE3","title":"Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2003-12","conditions":"Dementia, Alzheimer Disease","enrollment":415},{"nctId":"NCT00236574","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2001-05","conditions":"Dementia, Alzheimer Disease","enrollment":974},{"nctId":"NCT00236431","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2001-05","conditions":"Dementia, Alzheimer Disease","enrollment":1063},{"nctId":"NCT00035191","phase":"PHASE3","title":"A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2001-10","conditions":"Dementia, Vascular","enrollment":254},{"nctId":"NCT00416169","phase":"PHASE2","title":"A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2003-05","conditions":"Frontotemporal Dementia, Pick Complex","enrollment":41},{"nctId":"NCT00035204","phase":"PHASE4","title":"A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"","conditions":"Alzheimer Disease","enrollment":63},{"nctId":"NCT00077727","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2003-03","conditions":"Schizophrenia","enrollment":107},{"nctId":"NCT00253214","phase":"PHASE3","title":"Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2001-03","conditions":"Alzheimer Disease, Dementia","enrollment":973},{"nctId":"NCT00082602","phase":"PHASE3","title":"Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-05","conditions":"Alzheimer's Disease","enrollment":83},{"nctId":"NCT00645190","phase":"PHASE3","title":"A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2004-03","conditions":"Alzheimer Disease","enrollment":215},{"nctId":"NCT00645554","phase":"PHASE1","title":"A Single Dose, Cross-over Bioequivence Study Comparing Galantamine IR (Immediate Release) Table and Galantmine OS (Oral Solution) in Healthy Volunteers","status":"COMPLETED","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"","conditions":"Pharmacokinetics","enrollment":2},{"nctId":"NCT00253201","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"","conditions":"Alzheimer Disease, Dementia","enrollment":636},{"nctId":"NCT00309725","phase":"PHASE3","title":"A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"","conditions":"Alzheimer's Disease","enrollment":139},{"nctId":"NCT00253227","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1997-07","conditions":"Alzheimer Disease, Dementia","enrollment":387},{"nctId":"NCT00261573","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1998-12","conditions":"Alzheimer Disease, Vascular Dementia","enrollment":593},{"nctId":"NCT00240695","phase":"PHASE3","title":"A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2003-05","conditions":"Cognition Disorder, Nervous System Diseases, Mental Disorders","enrollment":724},{"nctId":"NCT00253188","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1997-02","conditions":"Alzheimer Disease, Dementia","enrollment":653},{"nctId":"NCT00301574","phase":"PHASE3","title":"An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2001-04","conditions":"Alzheimer Disease","enrollment":398},{"nctId":"NCT00304629","phase":"PHASE3","title":"Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2000-03","conditions":"Alzheimer Disease","enrollment":241},{"nctId":"NCT01039194","phase":"PHASE1","title":"Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-01","conditions":"Alzheimer Disease","enrollment":18},{"nctId":"NCT00216502","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Janssen-Cilag S.p.A.","startDate":"2001-08","conditions":"Alzheimer Disease, Dementia, Mental Disorders","enrollment":254},{"nctId":"NCT00216515","phase":"PHASE4","title":"The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2004-03","conditions":"Alzheimer Disease","enrollment":102},{"nctId":"NCT00637442","phase":"NA","title":"Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)","status":"UNKNOWN","sponsor":"University Hospital, Bonn","startDate":"2008-02","conditions":"Alzheimer's Disease","enrollment":30},{"nctId":"NCT01190761","phase":"PHASE1","title":"Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2004-12","conditions":"Healthy","enrollment":24},{"nctId":"NCT00181675","phase":"PHASE4","title":"A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2002-12","conditions":"ADHD","enrollment":40},{"nctId":"NCT01129479","phase":"NA","title":"Galantamine Treatment for Nonfluent Aphasia in Stroke Patients","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2004-10","conditions":"Aphasia, Stroke","enrollment":8}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"VISION BLURRED"}],"_approvalHistory":[],"publicationCount":57,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Galantamine (Reminyl)","genericName":"Galantamine (Reminyl)","companyName":"Janssen-Cilag Pty Ltd","companyId":"janssen-cilag-pty-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Galantamine inhibits acetylcholinesterase to increase acetylcholine levels in the brain, and also acts as an allosteric modulator of nicotinic receptors to enhance cholinergic neurotransmission. Used for Mild to moderate Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}